Actinium Announces New Data From Ongoing Phase 1/2 Trial of Actimab-A Demonstrating Safety and Robust Clinical Efficacy in High Risk Elderly Acute Myeloid Leukemia Patients Mar 18, 2015
Actinium to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference March 20th in New York City Mar 16, 2015
Major Bone Marrow Transplant Event Drives Significant Interest Among Leading Transplant Physicians for Upcoming Pivotal Trial of Iomab-B Feb 23, 2015
Actinium to Present at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on February 23rd Feb 18, 2015
Principal Investigator Dr. John Pagel to Brief Clinicians From Major Bone Marrow Transplant Centers on Upcoming Pivotal Trial of Iomab-B Feb 12, 2015
Actinium's Chief Medical Officer to Participate in the Next Gen Immunotherapeutics Panel at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on February 23rd Feb 9, 2015
